Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay

Robert C. Gosselin, Denis M Dwyre, William E. Dager

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Clinicians managing patients receiving the direct thrombin inhibitor dabigatran may benefit in being able to determine the amount of drug present in selected situations. This may include assessment of accumulation, concurrent drug interactions, or adequate removal from circulation. The ability to estimate the amount of dabigatran present using the chromogenic ecarin assay (ECA) requires further clarification. Objective: To describe the reliability of dabigatran measurements using a chromogenic ECA. Methods: This was an evaluation of the ECA method that incorporated assessment of imprecision, linearity, accuracy, carryover, and lower limits of detection or blank. Pooled normal plasma enriched with dabigatran at concentrations of 0, 25, 50, 75, 100, 125, 150, 200, 300, 400, and 500 ng/mL were sent blinded to 3 laboratories in the United States to compare our ECA results with those of laboratories reporting dilute thrombin time methods (HEMOCLOT thrombin inhibitor assay) for measuring dabigatran. Trough and peak levels from 35 patients were also compared with mass spectrophotometry for assessing ECA accuracy. Results: The within-run or day-to-day imprecision was less than 10%, with high linearity (R2 = 0.989) and high degree of accuracy (R2 = 0.985; slope = 0.908) for levels ranging between 18 and 470 ng/mL and no carryover at 0 ng/mL noted. The ECA approach appeared to be more reliable at lower dabigatran concentrations. Conclusions: The chromogenic ECA appears to be an effective approach to determine the amount of dabigatran present. Further insights are necessary to determine how it can be used to reduce thromboembolic or bleeding complications in patients receiving dabigatran.

Original languageEnglish (US)
Pages (from-to)1635-1640
Number of pages6
JournalAnnals of Pharmacotherapy
Volume47
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Thrombin Time
Antithrombins
Dabigatran
ecarin
Spectrophotometry
Drug Interactions
Thrombin
Limit of Detection
Hemorrhage
Pharmaceutical Preparations

Keywords

  • chromogenic ecarin assay
  • dabigatran
  • laboratory

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay. / Gosselin, Robert C.; Dwyre, Denis M; Dager, William E.

In: Annals of Pharmacotherapy, Vol. 47, No. 12, 12.2013, p. 1635-1640.

Research output: Contribution to journalArticle

Gosselin, Robert C. ; Dwyre, Denis M ; Dager, William E. / Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay. In: Annals of Pharmacotherapy. 2013 ; Vol. 47, No. 12. pp. 1635-1640.
@article{6d16eff88b89463ba729e46702d57227,
title = "Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay",
abstract = "Background: Clinicians managing patients receiving the direct thrombin inhibitor dabigatran may benefit in being able to determine the amount of drug present in selected situations. This may include assessment of accumulation, concurrent drug interactions, or adequate removal from circulation. The ability to estimate the amount of dabigatran present using the chromogenic ecarin assay (ECA) requires further clarification. Objective: To describe the reliability of dabigatran measurements using a chromogenic ECA. Methods: This was an evaluation of the ECA method that incorporated assessment of imprecision, linearity, accuracy, carryover, and lower limits of detection or blank. Pooled normal plasma enriched with dabigatran at concentrations of 0, 25, 50, 75, 100, 125, 150, 200, 300, 400, and 500 ng/mL were sent blinded to 3 laboratories in the United States to compare our ECA results with those of laboratories reporting dilute thrombin time methods (HEMOCLOT thrombin inhibitor assay) for measuring dabigatran. Trough and peak levels from 35 patients were also compared with mass spectrophotometry for assessing ECA accuracy. Results: The within-run or day-to-day imprecision was less than 10{\%}, with high linearity (R2 = 0.989) and high degree of accuracy (R2 = 0.985; slope = 0.908) for levels ranging between 18 and 470 ng/mL and no carryover at 0 ng/mL noted. The ECA approach appeared to be more reliable at lower dabigatran concentrations. Conclusions: The chromogenic ECA appears to be an effective approach to determine the amount of dabigatran present. Further insights are necessary to determine how it can be used to reduce thromboembolic or bleeding complications in patients receiving dabigatran.",
keywords = "chromogenic ecarin assay, dabigatran, laboratory",
author = "Gosselin, {Robert C.} and Dwyre, {Denis M} and Dager, {William E.}",
year = "2013",
month = "12",
doi = "10.1177/1060028013509074",
language = "English (US)",
volume = "47",
pages = "1635--1640",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "12",

}

TY - JOUR

T1 - Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay

AU - Gosselin, Robert C.

AU - Dwyre, Denis M

AU - Dager, William E.

PY - 2013/12

Y1 - 2013/12

N2 - Background: Clinicians managing patients receiving the direct thrombin inhibitor dabigatran may benefit in being able to determine the amount of drug present in selected situations. This may include assessment of accumulation, concurrent drug interactions, or adequate removal from circulation. The ability to estimate the amount of dabigatran present using the chromogenic ecarin assay (ECA) requires further clarification. Objective: To describe the reliability of dabigatran measurements using a chromogenic ECA. Methods: This was an evaluation of the ECA method that incorporated assessment of imprecision, linearity, accuracy, carryover, and lower limits of detection or blank. Pooled normal plasma enriched with dabigatran at concentrations of 0, 25, 50, 75, 100, 125, 150, 200, 300, 400, and 500 ng/mL were sent blinded to 3 laboratories in the United States to compare our ECA results with those of laboratories reporting dilute thrombin time methods (HEMOCLOT thrombin inhibitor assay) for measuring dabigatran. Trough and peak levels from 35 patients were also compared with mass spectrophotometry for assessing ECA accuracy. Results: The within-run or day-to-day imprecision was less than 10%, with high linearity (R2 = 0.989) and high degree of accuracy (R2 = 0.985; slope = 0.908) for levels ranging between 18 and 470 ng/mL and no carryover at 0 ng/mL noted. The ECA approach appeared to be more reliable at lower dabigatran concentrations. Conclusions: The chromogenic ECA appears to be an effective approach to determine the amount of dabigatran present. Further insights are necessary to determine how it can be used to reduce thromboembolic or bleeding complications in patients receiving dabigatran.

AB - Background: Clinicians managing patients receiving the direct thrombin inhibitor dabigatran may benefit in being able to determine the amount of drug present in selected situations. This may include assessment of accumulation, concurrent drug interactions, or adequate removal from circulation. The ability to estimate the amount of dabigatran present using the chromogenic ecarin assay (ECA) requires further clarification. Objective: To describe the reliability of dabigatran measurements using a chromogenic ECA. Methods: This was an evaluation of the ECA method that incorporated assessment of imprecision, linearity, accuracy, carryover, and lower limits of detection or blank. Pooled normal plasma enriched with dabigatran at concentrations of 0, 25, 50, 75, 100, 125, 150, 200, 300, 400, and 500 ng/mL were sent blinded to 3 laboratories in the United States to compare our ECA results with those of laboratories reporting dilute thrombin time methods (HEMOCLOT thrombin inhibitor assay) for measuring dabigatran. Trough and peak levels from 35 patients were also compared with mass spectrophotometry for assessing ECA accuracy. Results: The within-run or day-to-day imprecision was less than 10%, with high linearity (R2 = 0.989) and high degree of accuracy (R2 = 0.985; slope = 0.908) for levels ranging between 18 and 470 ng/mL and no carryover at 0 ng/mL noted. The ECA approach appeared to be more reliable at lower dabigatran concentrations. Conclusions: The chromogenic ECA appears to be an effective approach to determine the amount of dabigatran present. Further insights are necessary to determine how it can be used to reduce thromboembolic or bleeding complications in patients receiving dabigatran.

KW - chromogenic ecarin assay

KW - dabigatran

KW - laboratory

UR - http://www.scopus.com/inward/record.url?scp=84891680866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891680866&partnerID=8YFLogxK

U2 - 10.1177/1060028013509074

DO - 10.1177/1060028013509074

M3 - Article

C2 - 24259624

AN - SCOPUS:84891680866

VL - 47

SP - 1635

EP - 1640

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 12

ER -